Current stock page

Stock Analysis

Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis

Mirum Pharmaceuticals, Inc. (MIRM) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

MIRM Stock Analysis Summary

Mirum Pharmaceuticals, Inc. (MIRM) currently has an AIQ Score of 53/100, indicating a neutral setup. Value is the strongest factor at 57/100. Risk is the weakest current factor at 51/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

MIRM at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$93.99
AIQ Score53/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Buy
Market Cap$6.16B
P/E Ratio (TTM)-6.17
Forward P/E—
EPS (Q3 FY2026)-$0.62
Revenue (Q3 FY2026)$185.72M
Dividend Yield (TTM)0.00%
Beta1.07
Volume331.06K
52-week range$63.23-$130.00
RSI 1459.88
50-Day SMA$88.79
200-Day SMA$98.41
Analyst Price Target$156.89
Next EarningsFeb 24, 2027
As of Nov 13, 2026 · Market close

MIRMMirum Pharmaceuticals, Inc.

Healthcare / Biotechnology

Low Priority

In Line With Peers

NeutralEdge 5/10
$93.99+$0.66 (+0.71%)

Latest quote

  • Momentum
    54
  • Value
    57
  • Quality
    52
  • Risk resilience
    51
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

MIRM Stock Analysis Summary

Mirum Pharmaceuticals, Inc. (MIRM) currently has an AIQ Score of 53/100, indicating a neutral setup. Value is the strongest factor at 57/100. Risk resilience is the weakest current factor at 51/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, MIRM has AIQ Score of 53/100 with Value base of 57/100 and fading Risk resilience at 51/100. Wait for component alignment before adding exposure.

Healthcare · 0.71% stock move · MIRM classified in Biotechnology.

Current Evidence

NeutralMIRM is in a neutral AIQ regime; Value is the strongest visible factor at 57/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is MIRM Bullish or Bearish Right Now?

MIRM currently has a neutral overall setup. Value is the strongest factor at 57/100, while Risk Resilience is weakest at 51/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Price is +5.86% above its 50-day SMA.
  • - Analyst target implies +66.92% upside from the latest quote.
  • - Technical consensus has more buy votes than sell votes (33 vs 4).
Bear Case
  • - Price is -4.49% below its 200-day SMA.

Current Consensus

MIRM's Technical Analysis Consensus is currently Strong Buy, with 33 buy, 9 neutral, and 4 sell votes. MIRM's 14-day RSI is 59.88, which places the stock in a constructive momentum range. MIRM's beta is 1.07, indicating market sensitivity broadly in line with the market.

Signal Confidence
High agreement

What Changed in MIRM?

The largest recent change in MIRM is Momentum moving up by 8.0 points over the available 7-day comparison window. Value remains the strongest visible factor.

AIQ Score
+4.0
Momentum
+8.0
Quality
+1.0
Risk
+1.0

What Would Change the MIRM Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

MIRM Decision Framework

Public evidence layers, setup checks, and risk context for Mirum Pharmaceuticals, Inc..

Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis

Mirum Pharmaceuticals, Inc. has an AIQ Score of 53/100 in a Neutral regime. Value is strongest at 57/100. Beta is 1.07, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextMIRM is in a Neutral AIQ regime with score 53/100.
Signal ConflictThe primary conflict is that value leads at 57/100 while risk lags at 51/100.
Factor EvidenceMomentum 54/100 · Value 57/100 · Quality 52/100 · Risk 51/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthWait

Value is the strongest factor at 57/100.

TimingWait

Momentum is 54/100 and RSI (14) is 59.9.

Regime fitWait

MIRM is in a Neutral regime at 53/100.

Risk controlWait

Risk factor is 51/100 with beta 1.07 and annual volatility 48.6%.

ConflictPass

Current conflict: value leads at 57/100 while risk lags at 51/100.

AIQ Score
53/100
Price
$93.99
Beta
1.07
RSI (14)
59.9

MIRM Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

MIRM Fundamentals

MIRM valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$185.72M
Net income
-$40.77M
Free cash flow
-$5.62M
View full MIRM fundamental analysis

MIRM Technical Analysis

MIRM technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
59.88
Price vs SMA-50
+5.86%
View full MIRM technical analysis

MIRM Stock Catalysts

Track MIRM earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 24, 2027
Analyst target
$156.89
News items
5
View MIRM earnings and stock catalysts

MIRM Dividend Analysis

MIRM dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View MIRM dividend history and analysis

MIRM Financial Data

MIRM revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$185.72M
EPS
-$0.62
Periods
8
View MIRM financials

MIRM Risk Analysis

MIRM volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.07
Risk score
51/100
1Y volatility
48.60%
View MIRM risk analysis

MIRM Stock News

MIRM stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read MIRM stock news

MIRM vs Biotechnology Peers

Current peer cohort: MIRM · MLYS · NAMS · NBIX · NKTR. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
MIRM
Current stock
53/10057/10054/10051/1000.7948.60%Current
MLYS
Mineralys Therapeutics, Inc.
33/100—23/10035/100-1.4861.66%MIRM vs MLYS
NAMS
NewAmsterdam Pharma Company N.V.
41/10042/10022/10048/100-0.9153.82%MIRM vs NAMS
NBIX
Neurocrine Biosciences, Inc.
74/10077/10070/10069/1000.4935.22%MIRM vs NBIX
NKTR
Nektar Therapeutics
39/10047/10025/10041/100-0.1184.03%MIRM vs NKTR
Pairwise Compare links: MLYS · NAMS · NBIX · NKTRMIRM vs MLYSMIRM vs NAMSMIRM vs NBIXMIRM vs NKTRCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a MIRM stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for MIRM: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-6.17
As of Nov 13, 2026
Revenue growth
39.63%
Gross margin
81.70%
Current debt / equity
-13.72
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$185.72M
Quarter net income
-$40.77M
Quarter free cash flow
-$5.62M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bullish
RSI 14
59.88
MACD
2.13

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
51/100
Beta
1.07
Annual volatility
48.60%
Max drawdown
-38.36%

MIRM Stock FAQ

What is MIRM stock price today?

Mirum Pharmaceuticals, Inc.'s current stock price is $93.99. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is MIRM bullish or bearish right now?

MIRM's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is MIRM's market cap?

MIRM's market cap is $6.16B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is MIRM's current P/E ratio?

MIRM's current P/E ratio is -6.17 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is MIRM's RSI?

MIRM's 14-day RSI is 59.88 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is MIRM above its 50-day and 200-day moving averages?

MIRM is 5.86% from its 50-day SMA and -4.49% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is MIRM's next earnings date?

MIRM's next earnings date is currently listed as Feb 24, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does MIRM pay a dividend?

MIRM's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.